Search Results - "Boot E"

This result is not displayed to guests.
Login for full access.

Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia.

Authors: Fiksinski, A. M. Breetvelt, E. J. Lee, Y. J. et al.

Source: Psychological Medicine. Apr2019, Vol. 49 Issue 6, p1047-1054. 8p.

Subjects: Genetics of schizophrenia, Schizophrenia risk factors, Adaptability (Personality), Age distribution, Cognitive testing, Factor analysis, Health status indicators, Life skills, Mathematical models, Neuropsychological tests, Memory, Psychology of movement, Psychology, Psychoses, Regression analysis, 22q11 deletion syndrome

Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria.

Authors: Boot, E. Hollak, C. E. M. Huijbregts, S. C. J. et al.

Source: Psychological Medicine. Dec2017, Vol. 47 Issue 16, p2854-2865. 12p.

Subjects: Phenylketonuria, Brain, Cognition disorders, Comparative studies, Dopamine, Self-evaluation, Executive function, In vivo studies, Psychological factors, Adults, Psychology

Polycrystalline SiC growth and characterization

Authors: Ricciardi, C. Aimo Boot, E. Giorgis, F. et al.

Source: Applied Surface Science. Nov2004, Vol. 238 Issue 1-4, p331-335. 5p.

Subjects: Silicon, Spectrum analysis, Raman spectroscopy, Polycrystals

Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis.

Authors: Bakker, G. Caan, M. W. A. Schluter, R. S. et al.

Source: Psychological Medicine. Aug2016, Vol. 46 Issue 11, p2299-2311. 13p.

Subjects: Radiography, Psychoses risk factors, Biomarkers, Brain, Comparative studies, Magnetic resonance imaging, 22q11 deletion syndrome, Descriptive statistics

Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome.

Authors: de Koning MB Boot E Bloemen OJ et al.

Source: Journal of Psychopharmacology. Dec2012, Vol. 26 Issue 12, p1548-1560. 13p.

Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia - relationship with COMT Val108/158 Met polymorphism, gender and symptomatology.

Authors: Boot E Booij J Abeling N et al.

Source: Journal of Psychopharmacology. Jul2011, Vol. 25 Issue 7, p888-895. 8p.

Striatal D receptor binding in 22q11 deletion syndrome: an [²(3)I]IBZM SPECT study.

Authors: Boot E Booij J Zinkstok JR et al.

Source: Journal of Psychopharmacology. Oct2010, Vol. 24 Issue 10, p1525-1531. 7p.

This result is not displayed to guests.
Login for full access.

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.

Authors: Müller, A. R. den Hollander, B. van de Ven, P. M. et al.

Source: BMC Psychiatry. 1/4/2024, Vol. 24 Issue 1, p1-14. 14p.

Functional re-education at Hart house.

Authors: Boot, E. A.

Source: Textile World; January 26 1918, Vol. 53, p3495

Pharmacological Treatment of 22q11.2 Deletion Syndrome-related Psychoses.

Authors: Boot, E. Butcher, N. J. Vorstman, J. A. S. et al.

Source: Pharmacopsychiatry. 2015, Vol. 48 Issue 6, p219-220. 2p.

Overexpression of Chromosome 15q11-q13 Gene Products: A Risk Factor for Schizophrenia and Associated Psychoses?

Authors: Boot E Kant SG Otter M et al.

Source: American Journal of Psychiatry. Jan2012, Vol. 169 Issue 1, p96-97. 2p.

Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith-Magenis syndrome: protocol for a series of N-of-1 trials.

Authors: Müller, A. R. Zinkstok, J. R. Rommelse, N. N. J. et al.

Source: Orphanet Journal of Rare Diseases. 9/8/2021, Vol. 16 Issue 1, p1-9. 9p.

P.1.g.079 Dopaminergic neurotransmission in clinical and genetic high risk populations for psychosis.

Authors: Van Amelsvoort, T. Bloemen, O. Boot, E. et al.

Source: European Neuropsychopharmacology. Oct2013 Supplement 2, Vol. 23, pS236-S236. 1p.

AlSiTiN nanocomposite coatings developed via Arc Cathodic PVD: Evaluation of wear resistance via tribological analysis and high speed machining operations

Authors: Faga, M.G. Gautier, G. Calzavarini, R. et al.

Source: Wear. Sep2007, Vol. 263 Issue 7-12, p1306-1314. 9p.

P.3.b.024 Changes in white matter microstructure integrity of the limbic system after psychosis in 22q11 deletion syndrome seems to be associated with psychosis.

Authors: Bakker, I.M. Van Dijk, L. Caan, M.W.A. et al.

Source: European Neuropsychopharmacology. Sep2015 Supplement 2, Vol. 25, pS477-S478. 1p.

P.3.b.026 Differences in cortical morphology between 22q11.2 deletion syndrome patients and patients at ultra-high risk for psychotic disorders.

Authors: Bakker, G. Caan, M.W.A. Vingerhoets, W.A.M. et al.

Source: European Neuropsychopharmacology. Sep2015 Supplement 2, Vol. 25, pS478-S478. 1p.

P.1.i.010 Spectroscopy differences between at risk populations for psychosis.

Authors: Bloemen, O. Vingerhoets, W. Bakker, G. et al.

Source: European Neuropsychopharmacology. Sep2015 Supplement 2, Vol. 25, pS304-S305. 1p.

P.6.f.005 Prevalence of substance use and the relation with psychosis and catechol-O-methyltransferase in patients with chromosome 22q11 deletion syndrome.

Authors: Vingerhoets, W.A.M. Van Oudenaren, M.J.F. Van Duin, E.D.A. et al.

Source: European Neuropsychopharmacology. Sep2015 Supplement 2, Vol. 25, pS630-S630. 1p.